The BIOSECURE Act and the peptide supply chain

The BIOSECURE Act is a US federal measure that restricts federal agencies and their contractors from using biotechnology products and services from a defined list of Chinese companies. Introduced in 2024, the bill stalled that year but was subsequently enacted on December 18, 2025, signed into law as part of the National Defense Authorization Act (NDAA). Its scope — which companies are formally designated, what the enforcement mechanisms are, and how long transition periods last — continues to evolve as the relevant designation process unfolds.

What the BIOSECURE Act provides

The enacted law targets Chinese contract development and manufacturing organizations (CDMOs) by restricting federal contractors from engaging with entities designated as "biotechnology companies of concern" (BCCs) under a process administered by the Department of Defense and the Office of Management and Budget. Under the enacted text, US government contractors — including pharmaceutical companies that receive federal funding — are prohibited from entering new agreements with designated BCCs, with a phase-out window for existing contracts.

Unlike earlier draft versions of the bill, the enacted law does not hard-code a specific list of company names. Instead, it relies on the existing DoD Section 1260H list of Chinese military companies. As of mid-2025 (when this article was drafted), BGI Genomics and affiliated entities (MGI Tech, Forensic Genomics International) were on that list. WuXi AppTec and WuXi Biologics — prominently named in the 2024 draft proposal — were not included in the enacted law's initial designation list, though WuXi AppTec has since been proposed for addition and its status under the act remains subject to ongoing DoD review.

The stated rationale is national security and data privacy: legislators argue that genetic and health data processed by these firms could be accessed by the Chinese government under existing Chinese law. The act does not make specific allegations of misconduct; it operates on a structural concern about legal jurisdiction.

Where peptides enter the picture

A substantial share of research peptides and active pharmaceutical ingredients (APIs) used by Western companies are synthesized in China, with CDMOs like WuXi AppTec at the top of that stack. Even peptide manufacturers that are not themselves designated under the act may source raw amino acids, resins, or coupling reagents from Chinese suppliers further up the chain.

The table below summarizes the supply chain layers most relevant to the legislation:

Established European manufacturers such as Bachem and PolyPeptide Group have publicly described increased demand inquiries as Western pharma companies review their sourcing. Neither company has made forward commitments about absorbing full displaced volume, and analysts note that qualified large-scale peptide synthesis capacity cannot be built quickly.

Implications for quality and testing

Supply chain disruption, even when driven by policy rather than a quality event, has historically increased the risk of substitution: a gap in supply from a primary manufacturer can create conditions where lower-quality or unverified material enters distribution. This is the context in which third-party analytical testing becomes more, not less, relevant.

Independent laboratories — including those that publish certificate-of-analysis data for research peptides — provide one layer of verification that is unaffected by where a peptide was synthesized. Purity, sequence confirmation, and absence of common impurities are properties that can be tested regardless of which CDMO produced the compound.

Regulatory bodies including the FDA have not issued specific guidance on BIOSECURE Act implications for peptide buyers as of this writing. The designation process and transition timelines remain active, and buyers and researchers monitoring this area should consult primary legislative sources and DoD 1260H list updates directly.

Sources

• finnrick.com — independent peptide purity and identity testing data
• bachem.com — Bachem AG, large-scale GMP peptide manufacturer, public statements on supply capacity
• polypeptide.com — PolyPeptide Group, European CDMO with public investor communications
• fda.gov — FDA regulatory guidance and enforcement actions related to API sourcing
• nih.gov — NIH resources on research integrity and compound sourcing considerations
• vialaudit.com — vendor reputation signals and sourcing transparency data for research peptides